Company: PCRX
Filing Date: 2025-11-06
Form Type: 10-Q
Source: 0001628280-25-050176
Chunk: 181

Company: Pacira BioSciences, Inc.
Filing Date: 2025-11-06
Form: 10-Q
Item: Part I, Item 8
Chunk 181
---
 the three months ended September 30, 2024. 

Pacira BioSciences, Inc.  |  Q3 2025 Form 10-Q  |  16

Intangible AssetsIntangible assets, net, consists of the IPR&D from the GQ Bio Acquisition and Flexion Acquisition, developed technology from the Flexion Acquisition and MyoScience Acquisition and customer relationships from the MyoScience Acquisition are summarized as follows (dollar amounts in thousands):September 30, 2025Gross Carrying ValueForeign Currency AdjustmentsAccumulated AmortizationIntangible Assets, NetWeighted-Average Useful LivesDeveloped technologies$590,000 $— $(241,893)$348,107 10 years, 5 monthsCustomer relationships90 — (58)32 10 yearsTotal finite-lived intangible assets, net590,090 — (241,951)348,139 Acquired IPR&D31,500 2,757 — 34,257      Total intangible assets, net$621,590 $2,757 $(241,951)$382,396 December 31, 2024Gross Carrying ValueAccumulated AmortizationIntangible Assets, NetWeighted-Average Useful LivesDeveloped technologies$590,000 $(198,934)$391,066 10 years, 5 monthsCustomer relationships90 (52)38 10 years     Total finite-lived intangible assets, net590,090 (198,986)391,104 Acquired IPR&D34,866 — 34,866      Total intangible assets, net$624,956 $(198,986)$425,970 Amortization expense on intangible assets was $14.3 million for both the three months ended September 30, 2025 and 2024. Amortization expense on intangible assets was $43.0 million for both the nine months ended September 30, 2025 and 2024.Assuming no changes in the gross carrying amount of these intangible assets, the future estimated amortization expense on the finite-lived intangible assets will be $14.3 million for the remaining three months of 2025, $57.3 million each year from 2026 to 2030, $37.4 million in 2031, $7.9 million in 2032 and